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2Abstract
The deficiency of dystrophin, a critical membrane stabilising protein, in the mdx 
mouse causes an elevation in intracellular calcium in myocytes. One mechanism that 
could elicit increases in intracellular calcium is enhanced influx via the L-type 
calcium channels. This study investigated the effects of the dihydropyridines BayK 
8644 and nifedipine and alterations in dihydropyridine receptors in dystrophin-
deficient mdx hearts. A lower force of contraction and a reduced potency of 
extracellular calcium (P<0.05) was evident in mdx left atria. The dihydropyridine 
agonist Bay K 8644 and antagonist nifedipine had 2.7 and 1.9 fold lower potencies in 
contracting left atria (P<0.05).   This corresponded with a 2.0 fold reduction in 
dihydropyridine receptor affinity evident from radioligand binding studies of mdx 
ventricular homogenates (P<0.05). Increased ventricular dihydropyridine receptor 
protein was evident from both radioligand binding studies and Western blots and was 
accompanied by increased mRNA levels (P<0.05). Patch clamp studies in isolated 
ventricular myocytes showed no change in L-type calcium current density, but 
revealed delayed channel inactivation (P<0.05). This study indicates that a deficiency 
of dystrophin leads to changes in dihydropyridine receptors and L-type calcium 
channel properties that may contribute to enhanced calcium influx. Increased influx is 
a potential mechanism for the calcium overload observed in dystrophin deficient
cardiac muscle. 
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3Introduction
Dystrophin is an integral subsarcolemmal protein essential for stabilising both the 
dystrophin associated glycoprotein complex (12) and the membrane of cardiac 
myocytes during contractions (7). The absence of dystrophin is the primary molecular 
basis of Duchenne Muscular Dystrophy (DMD), a fatal X-linked neuromuscular 
disorder affecting 1 in 3500 live male births (11). Cardiac dysfunction is observed 
frequently, with cardiomyopathy shortening the lifespan of a significant proportion of 
boys with DMD (5, 10, 15, 16, 23). In addition to congestive heart failure, other 
cardiac manifestations of DMD include altered heart rate variability, arrhythmias, 
conduction defects and fibrosis (17). Similarly, a reduced dystrophin expression is the 
primary basis of congestive heart failure in X-linked cardiomyopathy and Beckers 
Muscular Dystrophy (6), with cardiac transplantation being undertaken as a long term 
treatment option.
The dystrophin deficient mdx mouse arose as a spontaneous mutation from a colony 
of C57BL10 ScSn mice, and has been widely used as an animal model of DMD for 
research investigating skeletal muscle dysfunction. However, the cardiovascular 
manifestations caused by dystrophin deficiency in the mdx have not been reported 
extensively. We have previously reported altered responsiveness to -adrenoceptor 
and muscarinic receptor stimulation in young (12-14 week old) mice as well as a 
reduced efficacy and potency of calcium (20). In old mdx males (12 months), a 
lowered efficacy and potency of (-)-isoprenaline and reduced 1-adrenoceptor affinity 
is evident (19).
4Isolated cardiac myocytes (1, 13) and skeletal muscles (31, 32) from mdx mice and 
patients with DMD (3) exhibit elevated intracellular calcium. This calcium overload 
can lead to decreased myocyte function and myocyte necrosis (4) resulting from 
calcium dependent proteolysis (30). Furthermore, mdx mice have been shown to 
exhibit dysfunctional calcium handling in both skeletal (28) and cardiac (21)
myocytes. Cardiac calcium overload could potentially be due to a leaky cell 
membrane as postulated in skeletal muscle (31) or may result from alterations in 
influx or efflux, intracellular calcium handling, sarcoplasmic reticulum storage, 
release, sequestration or a combination of these mechanisms. 
The major source of calcium influx across the cardiac cell membrane is the L-type 
calcium channel. This channel consists of a complex of 5 subunits, with the 1 subunit 
being the channel forming, voltage-sensing component and containing the binding site 
for dihydropyridine (DHP) compounds such as the antagonist nifedipine and agonist 
Bay K 8644. This 1-subunit, also commonly known as the dihydropyridine receptor 
(DHPR), is a defining feature of cardiac L-type calcium channels and is localised 
within the cardiac T-tubule system, which is where dystrophin is also located (25). 
Thus the primary aim of this study was to examine the consequences of dystrophin 
deficiency on the DHPRs as a marker of L-type calcium channels regulating calcium 
influx. 
5Methods and Materials
All experimental protocols were approved by the University of Southern Queensland 
Animal Ethics committee under the guidelines of the National Health and Medical 
Research Council of Australia which conform to the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. Male muscular dystrophy X-
linked (mdx) mice and their control C57BL10ScSn (C57) were used at 12-14 weeks of 
age. Mice were fed standard mouse chow ad libitum and maintained on a 12 hr 
light/dark cycle. 
Tissue Bath Experiments
Animals were anaesthetised by excess CO2 inhalation and euthanased by 
exsanguination prior to excision of their hearts. Left atria were dissected free in cold, 
carbogenated (95%O2; 5%CO2) Tyrodes physiological salt solution (TPSS in mM: 
NaCl 136.9, KCl 5.4, MgCl2.H2O 1.05, NaH2PO4.2H2O 0.42, NaHCO3 22.6, 
CaCl2.2H2O 1.8, glucose 5.5, ascorbic acid 0.28, Na2EDTA 0.05). A stainless steel 
hook was placed in one end of each atrium to connect that atrium to the tissue holder. 
A silk thread was tied to the other end of the atrium to connect it to a force transducer 
(FT-102, CB Sciences, Milford, MA, USA) to measure force of contraction. Atria 
were subsequently suspended in warm (35±1°C), carbogenated TPSS in tissue baths. 
Data were recorded via a PowerLab system (AD Instruments) using Chart 3.5.6. Left 
atria were field stimulated (AMPI Master 8 stimulator; 1 Hz, 5 ms duration, 20% 
above threshold) and maintained under optimal preload. Tissues were allowed 45 min 
to equilibrate with repetitive washes. At the completion of all experiments, the atria 
6were removed, blotted and weighed. There was no significant difference between the 
blotted masses of the atria taken from mdx and C57 so all force data are given as mN.
Nifedipine and Bay K 8644 Concentration Response Curves
Concentration-response curves were generated to calcium chloride to determine the 
maximum force of contraction attainable by the tissue. The tissues were then washed 
repetitively over 30 min to return the contractility to normal, and a concentration-
response curve measuring the negative inotropic effects of the DHP antagonist 
nifedipine was generated. In order to avoid indirect receptor-mediated effects of 
endogenous noradrenaline possibly released by Bay K 8644, tissues were incubated 
with the -adrenoceptor antagonist propranolol and -adrenoceptor antagonist 
prazosin for 30min before the concentration-response curve to Bay K 8644 was 
generated. As Bay K 8644 is sensitive to light of wavelengths below 450nm, all 
handling and experiments with Bay K 8644 were carried out under protection from 
light. After experiments with Bay K 8644, the organ baths were cleaned with nitric 
acid to eliminate contamination of glassware and then flushed repeatedly with 
distilled water.
Radioligand Binding 
Ventricular tissues were snap frozen in liquid nitrogen and stored at -70°C. For each 
experiment two ventricles were pooled to obtain sufficient membrane for five points 
on a saturation curve. Two ventricles were homogenized at 24 000 rpm by a Heidolph 
DIAX 600 after being thawed in Tris incubation solution (in mM: Tris HCl 50, EGTA 
5, EDTA 1, MgCl2 4, Ascorbic Acid 1, Trizma Base 50; pH 7.4 adjusted with NaOH). 
7The homogenate was centrifuged at 1000g and the pellet discarded. The supernatant 
was centrifuged at 100 000g and the supernatant discarded. The membrane fraction 
was then resuspended in Tris incubation buffer and subsequently diluted to 1mg/mL 
protein after measuring the protein content (Biorad Protein Assay Kit). Membrane 
(200µg) was incubated with increasing concentrations of [3H]-PN 200-110 (0.1-2nM) 
while non-specific binding was determined by the addition of 0.1mM nifedipine. 
Samples were incubated for 60 min at 35°C, and the incubation was then halted with 
the addition of 4mL ice-cold Tris incubation buffer. Samples were vacuum filtered 
over Whatman GFB filters and washed four times with ice-cold Tris wash buffer (in 
mM: Tris 50, pH 7.4). Filters were incubated overnight with scintillant and counted 
the following morning. Preliminary experiments confirmed that receptor affinity and 
density were not altered significantly by freezing and storing the tissues. Similarly, a 
series of preliminary experiments revealed that an incubation period of 60 min at 35ºC 
and a protein concentration of 200µg were optimal.
RT-PCR
Animals were anaesthetised with sodium pentobarbitone and euthanased by 
exsanguination before the hearts were excised. The ventricles and left atria were 
dissected free in TPSS and placed in RNAlater™ (Ambion) RNA stabilisation reagent 
for storage at -20°C. RNA extraction was performed with the QIAGEN RNeasy®
Mini Kit, utilising no more than 30mg of tissue per sample obtained from the apex of 
the left ventricle or the whole left atria. The tissue was lysed using a polytron rotor-
stator homogeniser in proprietary buffer containing guanidinium thiocyanate to 
liberate RNA prior to the extraction procedure. RNA was isolated via binding to a 
8silica-gel-based membrane during a number of centrifugation procedures as per the 
manufacturer’s instructions. 
RT-PCR was performed by the two-tube method using QIAGEN Omniscript™
Reverse Transcriptase and QIAGEN HotStarTaq™ DNA Polymerase. Tubes 
containing the reaction mixture were incubated in a Corbett Research PC-960C 
thermocycler. 0.2µM of each 2-subunit primer (TCC AGT TTA TAC TAC TTT 
GGC TGG T sense; ACT GAG GGC TCA TGT TTT GG antisense) or GAPDH 
primer (TTA GCA CCC CTG GCC AAG G sense; CTT ACT CCT TGG AGG CCA 
TG antisense); and HotStarTaq™ DNA Polymerase. PCR product was visualised 
following gel electrophoresis by ethidium bromide staining and UV transillumination 
in an AlphaImager 2200 MultiImage cabinet. Spot densitometry was performed using 
AlphaEase and the ratio of DHPR band intensity to GAPDH band intensity was 
calculated for each sample to allow a semi-quantitative comparison. 
Western Blotting 
Total protein was extracted by homogenising frozen ventricles in lysis buffer (4% 
SDS, 125 mM Tris-HCl pH 6.8, 40% glycerol, 50 mM DTT) containing Protease 
Inhibitor Cocktail (Sigma) and 0.5 mM phenylmethylsulfonylfluoride. Proteins (60 
µg) were separated on SDS-PAGE using a NuPAGE precast 4-12% Bis-Tris 
polyacrylamide gel and MOPS SDS running buffer (Invitrogen). After 
electrophoresis, proteins were transferred to a polyvinylidene difluoride membrane 
(Amersham). Transfer was confirmed by staining the membrane with Ponceau S stain 
(0.1% Ponceau S in 5% acetic acid). For detection of the 1C subunit, the top half of 
9the membrane was blocked in 1x Tris-buffered saline-Tween 20 containing 5% BSA 
and 0.1% Tween 20. This was followed by incubation with a 1:200 dilution of anti-
1C antibody (Sigma) at 4oC overnight and afterwards for 1 hour in a 1:10000 dilution 
of peroxidase-conjugated antibody (goat anti-rabbit polyclonal, Sigma). 
For detection of -actin, the lower half of the membrane was blocked in 1x Tris-
buffered saline-Tween 20 containing 5% skim milk powder and 0.05% Tween 20. 
This was followed by incubation with a 1:1000 dilution of anti-actin monoclonal 
antibody (Clone AC-40, Sigma) at room temperature for 90 minutes and afterwards
for 1 hour in a 1:6000 dilution of peroxidase-conjugated antibody (rabbit anti-mouse 
polyclonal, DakoCytomation). The immunoreactive bands on both western blots were 
visualised using ECL Plus and Hyperfilm ECL (Amersham). The western blots were 
analysed using Scion Image. The 1C protein was normalised to -actin to account for 
possible loading differences. 
Patch Clamp
Animals were anaesthetised by sodium pentobarbitone (70 mg/kg) and euthanased by 
exsanguination prior to excision of their hearts. The aorta was cannulated and the 
hearts suspended on a Langendorff system for perfusion with calcium free solution (in 
mM: NaCl 100; KCl 5; KH2PO4 1.2; MgSO4 5; Taurine 50; HEPES; 10; Glucose; 20; 
Creatine 10) at 37°C for 5 minutes followed by perfusion with collagenase type II 
solution (Worthington), 1% bovine zero albumin (BSA; Sigma), 0.08 mg/ml protease
(Sigma) for 12 to 18 minutes. The ventricles were then removed and crudely 
dissociated with scissors prior to addition of cell Tyrode solution (in mM: NaCl 100; 
KCl 5; KH2PO4 1.2; MgSO4 5; Taurine 50; HEPES; 10; Glucose; 20; Creatine 10)   
containing 0.4 mM CaCl2. After 10 minutes, this solution was aspirated and replaced 
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sequentially with solution containing 0.8 and finally 1.2 mM CaCl2  to produce 
calcium tolerant myocytes. 
Cells were placed in a 0.5 mL perfusion chamber, allowed to settle for 5 minutes and 
then perfused at room temperature with oxygenated Extracellular solution (in mM:
NaCl 50; MgCl2 3; CaCl2 1.8; KCl 3; TEA-Cl 90; glucose 7.7; HEPES 10; pH 7.4). 
Cells were patched using fire polished electrodes (1.5 – 2.5 M) pulled from 
filamented borosilicate glass (World Precision Instruments) filled with electrode 
solution (in mM: CsF 135; NaCl 10; HEPES 10; EGTA 10; glucose 7.7; MgATP 2; 
pH 7.2).  Cell recordings were obtained using a HEKA EPC-9. Cell capacitance was 
recorded and then cells were stepped from a holding potential of -70 mV to -40mV for 
40msec to inactivate the sodium current.  Cells were then stepped in 10 mV 
increments from -40 mV up to + 60 mV for 200 msec durations at 0.2 Hz.  Initial 
experiments confirmed recordings of L-type calcium currents by verifying a lack of 
effect by 1 µM tetrodotoxin and a concentration-dependent inhibition of L-type 
calcium current by verapamil (1-10 µM) and cadmium (50 µM).  Current density was 
calculated by dividing current amplitude by cell capacitance (pA/pF).
Reagents and Data Analysis
All reagents and pharmacological compounds were purchased from Sigma-Aldrich 
except where otherwise indicated. Data are presented as mean ± SE of the number (n)
of experiments. Data were compared using Student's two tailed t-test and a P<0.05 
was considered statistically significant.
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Results
Prior to conducting the concentration-response curves to the dihydropyridines the mdx
left atria had a lower basal force of contraction (1.50±0.17mN) compared to C57 
(1.91±0.18mN; P<0.05).  A subsequent concentration-response curve to calcium 
chloride (Figure 1A) revealed increases in contractile force, however when 
normalized to the basal force of contraction the percentage change in both tissues was 
found to be similar.  Of interest was the potency (EC50) values calculated from this 
data that showed a significant difference in mdx when compared to C57 (mdx
3.40±0.08x10-3 M, C57 3.15±0.10x10-3 M; P<0.05)
Nifedipine reduced the force of contraction similarly in left atria from both mdx and 
C57 but was significantly less potent in left atria from mdx (EC50 values: mdx
3.47±0.55x10-8 M; C57 1.78±0.40x10-8 M, P<0.05 Fig. 1A). A strain potency ratio for 
nifedipine was calculated by dividing the EC50 of nifedipine in mdx by the EC50 of 
nifedipine in C57 to give a value of 1.9. Bay K 8644 elicited a strong positive 
inotropic effect in both strains producing a similar efficacy to calcium. Although the 
efficacy (as a percent of calcium chloride) was not different between the two strains, a 
reduced potency (EC50 values mdx 7.94±0.55x10-7 M; C57 2.95±0.34x10-7 M, 
P<0.05 Fig. 1B) was again evident in mdx. The strain potency ratio for Bay K 8644 
was 2.7, which is similar to the ratio obtained for nifedipine. The solvent ethanol 
elicited a weak negative inotropic effect at the maximum solvent concentration, but 
this was completely overcome by the pronounced positive inotropic effect of Bay K 
8644.
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Radioligand binding experiments revealed a significantly greater density of DHPRs in 
mdx (Bmax 99.2±7.0 fmol/mg) compared to C57 (Bmax 74.5±9.4 fmol/mg; Fig. 2A, 
P<0.05) with a strain ratio (Bmax mdx /Bmax C57) of 1.3. The affinity of [3H]-PN 
200-110 was also reduced significantly in mdx (Kd 0.3677±0.08nM) compared to C57 
(Kd 0.1789±0.08nM) (Fig. 2A and B, P<0.05). The strain potency ratio (Kd mdx /Kd 
C57) was 2.0, a similar ratio to that observed in the functional tissue bath studies 
utilizing nifedipine and Bay K 8644. 
To confirm the result of increased DHPR protein observed in the radioligand binding 
study, immunoblotting was also conducted on ventricular myocardium.  Again this 
revealed increased DHPR protein in the mdx (Fig 2C).   This was supported by the 
observation that ventricular DHPR mRNA was significantly higher (P<0.005) in mdx
compared to C57 (Fig. 2D) when corrected for the amount of total mRNA by using 
the GAPDH samples. The strain ratio (band intensity mdx /band intensity C57) for 
ventricular mRNA was 2.3. The left atrial DHPR mRNA was also higher in mdx 
compared to C57, although this did not reach statistical significance (P=0.07). The 
strain ratio for atrial mRNA for DHPRs was 2.0. The ubiquitous -actin was also used 
as a housekeeper gene (data not shown) and produced qualitatively similar data to 
GAPDH normalisation.
Patch clamp experiments were then conducted to determine if the increased DHPR 
expression resulted in a larger current amplitude. The currents were not inhibited by 
tetrodotoxin, but were dose-dependently inhibited by verapamil and cadium 
confirming the appropriateness of the experimental conditions (data not shown). 
There was no significant difference in whole cell membrane capacitance (mdx 161±10 
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pF, C57 147±13 pF: n=10) and no significant difference in peak current density at a 
test potential of 0 mV (mdx 4.67±0.39 pA/pF, C57 5.45±0.58 pA/pF). However, 
further analysis revealed that the time to 90% inactivation of the L-type current was 
increased in mdx myocytes compared to C57 myocytes (P<0.05: Fig 3).  
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Discussion
This study is the first to measure the properties of DHPRs in dystrophin-deficient 
myocardium and shows a reduced potency to both a DHPR agonist and antagonist, 
reflected by reduced receptor affinity, upregulation of DHPR mRNA and protein and 
delayed inactivation of the L-type calcium current. 
Alterations in receptor regulation are a commonly observed phenomenon in 
cardiovascular disease states. Such alterations are generally evidenced initially by 
impaired potencies or efficacies to agonists which reflect changes in receptor 
stimulus, however, this study showed a similar difference in potency with the DHPR 
antagonist nifedipine. This potency difference can be explained by a lowered receptor 
affinity (higher Kd) as observed in the radioligand binding studies which utilised
antagonists and thus are not dependent on receptor stimulus and agonist efficacy.  
A possible mechanism that could affect the affinity of DHPRs is a change in the 
proportion of channels in the inactivated state which could be reflected by a change in 
the cell membrane potential, with depolarisation of the cardiac resting membrane 
potential causing an increase in DHPR affinity and thus presumably hyperpolarisation 
causing a decrease in DHPR affinity (2). However, microelectrode studies in left atria 
of mdx and C57 mice utilising the same conditions as those in the tissue bath studies 
did not show any difference in resting membrane potential with or without a calcium 
channel antagonist present (data not shown), eliminating this as a basis for the 
difference in DHPR affinity in the tissue bath studies. Furthermore, the difference in 
receptor affinity was maintained in the radioligand binding studies, where the 
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influence of the membrane potential is eliminated. This provides clear evidence that a 
change in receptor affinity is not due to changes in membrane potential. 
Another influence affecting DHPR affinity is the concentration of free calcium. Using 
[3H]-PN 200-110 in radioligand binding studies, Peterson and Catterall (26) showed 
that divalent ions cause a biphasic effect on the affinity of DHPRs, with a low free 
calcium causing an increase in affinity, while a high free calcium causes a significant 
decrease in affinity. It is therefore, highly feasible that the calcium overload observed 
in mdx myocytes is a mediator responsible for the lowered affinity state of the DHPRs 
observed in the atrial contractility studies. However, in DHPR radioligand binding 
studies, calcium is not added to the incubation buffer and chelators such as EGTA are 
also present. This then eliminates any acute effects of calcium on modifying the 
affinity state of the DHPRs within such studies. Given that a lowered affinity for [3H]-
PN 200-110 was still observed, this may suggest that chronic in vivo elevation of 
intracellular calcium may cause a more rigid conformational change in DHPRs, that is 
subsequently maintained in isolated membranes. 
Alternatively, a disruption in DHPR localization due to dystrophin deficiency may be 
possible. DHPRs are located in the transverse tubules (T tubules) of the myocyte 
which is also the major site where cardiac dystrophin is located (25, 29). Furthermore, 
dystrophin has been suggested to play a role in anchoring or modulating the activity 
of cardiac DHPRs (24), among other channels (8). Therefore, the deficiency of 
dystrophin could result in a direct defect in the DHPR that in turn may contribute to 
the observed reduction of potency in mdx cardiac tissues and a compensatory increase 
in DHPRs. It is highly probable that an increase in intracellular calcium is the cause of 
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the elevated DHPRs as Davidoff et al (8) reported that incubation of adult rat 
ventricular myocytes in high extracellular calcium (4.8 mM)  showed remarkably 
similar changes to those reported in the current study, including elevated DHPR 
mRNA levels 1.5 fold and DHPR density 2 fold. 
Clearly, if an elevation of DHPRs is evident, then an alteration in the L-type calcium 
current could be expected. This current study using 12-14 week old mice showed no 
change in current density between mdx and C57 confirming previous findings by 
Alloatti et al (1) who utilised mdx mice (of an unstated age) and Sadeghi et al (27)
who utilised cultured neonatal cardiac myocytes from 1 to 4 day old mdx mice. The 
basis for the lack of change in current density has not been ascertained to date and 
requires further investigation.  Possible mechanisms could be either an uncoupling 
and/or mislocalisation of additional DHPR (1c) subunits from the remaining L-type 
calcium channel subunits or an elevation in intracellular calcium reducing the driving 
force for calcium influx (9).
Although no change in current density was evident, a significant delay in inactivation 
of the L-type calcium current in adult mdx myocytes was observed further confirming 
similar findings obtained using neonatal mdx myocytes (27). Inactivation of L-type 
calcium channels is controlled by voltage and calcium-dependent mechanisms (18).  
A previous study utilising neonatal mdx myocytes using barium as the charge carrier 
instead of calcium, since it does not contribute effectively in mediating ion-dependent 
inactivation, showed that dystrophin deficiency alters L-type calcium channel 
inactivation by a shift in the voltage dependence of activation.  The current study used 
calcium as the charge carrier and as such allows a contribution of calcium-dependent 
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inactivation mechanisms. Such inactivation will thus be affected by alterations in 
calcium handling proteins such as SERCA with a reduced SERCA activity having 
been shown to slow calcium dependent inactivation (22). The mdx mouse has been 
reported to have reduced expression of SERCA, suggesting that calcium-dependent 
inactivation may also be slowed in mdx cardiac myocytes. Finally, the lack of 
dystrophin may also alter calcium dependent L-type channel inactivation directly 
since dystrophin may bind directly to calcium channels to affect inactivation (27).  
The result of the delay in inactivation could be a contributor to the further 
development of calcium overload in mdx cardiac myocytes which in turn would 
directly affect contractility. 
Distinct differences in contractility were observed with a significantly lower force of 
contraction from left atria of mdx compared to C57 mice evident prior to the addition 
of drugs in all of the functional experiments undertaken. This impaired capacity to 
generate force remained in spite of elevated extracellular calcium as previously 
reported (19, 20). Interestingly, the potency of calcium is also lowered when 
conducting a concentration-response curve to extracellular calcium. This reduction in 
potency to calcium and reduced capacity to generate force is indicative of a reduced 
sensitivity of the contractile proteins to calcium. One possible explanation for this is 
that chronically elevated intracellular calcium such as that observed in dystrophic 
muscles could cause a significant reduction in myofilament sensitivity (14).
In conclusion, dystrophin is essential for normal regulation of the L-type calcium 
current, DHPRs and cardiac contractility. The delayed inactivation of the L-type 
calcium current is a likely contributor to the elevation in intracellular calcium in the 
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dystrophic heart, although other mechanisms such as calcium sequestration or calcium 
leak from the sarcoplasmic reticulum may also be involved. The elevation in 
intracellular calcium is likely to contribute to the incidence of arrhythmias in DMD as 
well as the altered cardiac contractility. 
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Figure Legends
Figure 1 (A) Effect of nifedipine on left atria (n=8). EC50 values for mdx () 
3.47±0.55 x10-8M and for C57 () 1.78±0.40x10-8M (P<0.05). Response to 
increasing concentrations of extracellular calcium also shown (mdx (), C57 ()
revealing a significant difference in potency and efficacy to calcium (P<0.01). (B) 
Responses to Bay K 8644 in isolated mdx () and C57 () atria. Concentration-
response curve to Bay K 8644 in left atria (n=8). EC50 values for mdx 7.94±0.55x10-
7M and for C57 2.95±0.34x10-7M (P<0.05). See text for basal forces recorded at 1.8 
mM calcium. 
Figure 2 (A and B) Radioligand binding experiments from mdx (open: n= 15 
experiments; 30 ventricles) and C57 (filled: n = 19 experiments; 38 ventricles) in 
response to increasing concentrations of [3H]-PN 200-110 (0.1-2nM). Non-specific 
binding was determined by the addition of 0.1M nifedipine. There is a significant 
difference between mdx and C57 for both Kd (2A) and Bmax (2B) (P<0.05). (C)
Normalised data from Western blots of mdx and C57 ventricles showing evidence of 
increased DHPR protein in the mdx ventricles (n=3). (D) RT-PCR results from mdx
and C57 dihydropyridine receptor mRNA from ventricles and left atria (n=4). Band 
intensity was normalised to the amount of mRNA present by comparing each DHPR 
sample to its corresponding GAPDH sample. Ventricular mRNA was significantly 
higher in mdx (P<0.005) compared to C57. * indicates P<0.05. ** indicates P<0.01.
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Figure 3. Calcium currents from mdx and C57 myocytes (n=10).  (A) Original 
recordings of I-V traces for calcium currents from mdx and C57 cardiac myocytes
indicating similar current amplitude. (B) Original recording of a calcium current from  
mdx (solid) and C57 (dashed) cardiac myocytes revealing the delay of inactivation in 
the mdx myocyte.  (C) ICa -V relationships from mdx and C57 cardiac myocytes 
showing no significant differences in shapes of the curves. (mdx open, C57 filled) (D) 
Time to 90% inactivation showing a significant increase in inactivation time in mdx 
myocytes.(mdx open, C57 filled) * indicates P<0.05.
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